AP NEWS
Related topics

Stocks mixed...New Europe copyright regs...Survey: Britain still hot for investment

April 15, 2019

SINGAPORE (AP) — World stocks were mixed Monday after the U.S. and China said they were closing in on a trade deal, without giving a timeline for when negotiations would wrap up. Futures point to a mixed opening on Wall Street. Benchmark U.S. crude fell but remains above $63.50 per barrel. The dollar weakened against the yen and the euro.

LONDON (AP) — The European Union has approved a copyright rule that aims to give more protection to artists and news organizations but which critics say will stifle freedom of speech and online creativity and punish smaller web companies. Artists, celebrities and tech experts have spoken out both in favor and against the EU directive, which the 28 member states are required to adopt as law and got final approval from the European Council Monday.

LONDON (AP) — Brexit may be causing all sorts of uncertainty in Britain but it doesn’t seem to be putting off foreign investors. In a survey on corporate deal-making published Monday, consulting and accounting firm EY says Britain is the top investment destination in the world for the first time in the report’s 10-year history — overtaking the United States, which has held the top spot since 2014.

NEW YORK (AP) — Mainstream retailers are leaping into the world of products like skin creams and oils that tout such benefits as reducing anxiety and helping you sleep. The key ingredient? CBD, or cannabidiol, a compound derived from hemp and marijuana that doesn’t cause a high. Retailers are taking advantage of the booming industry even as its legal status and health benefits remain murky. And the flood of products is only testing how federal regulators can police it. CBD has been cropping up in everything from dog treats to bath balms in the past few months.

UNDATED (AP) — A drug that’s used to help control blood sugar in people with diabetes has now been shown to help prevent or slow kidney disease, which causes millions of deaths each year and requires hundreds of thousands of people to use dialysis to stay alive. Doctors say it’s hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic. The study tested Janssen Pharmaceuticals’ drug Invokana. Results are in the New England Journal of Medicine.